Intrasense SA stock analysis
Intrasense SA (I8S) Stock Price & Analysis
I8S Stock Chart & Stats
- Day’s Range
- EUR 0.18 - EUR 0.18
- 52-Week Range
- EUR 0.16 - EUR 0.38
- Previous Close
- EUR 0.20
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.82M
- Enterprise Value
- EUR 11.76M
- Total Cash (Recent Filing)
- EUR 1.44M
- Total Debt (Recent Filing)
- EUR 1.37M
- Price to Earnings (P/E)
- ―
- Beta
- 0.26
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Subscription Model
A subscription-based licensing model creates recurring revenue and service relationships with healthcare institutions. Over months this improves revenue predictability, supports multi-year customer retention, and can enable more stable cash flow to fund product development and support investments.
Focused Imaging Software Portfolio
Specialization in advanced medical imaging positions the company in a niche with durable demand from radiology workflows. Domain-focused products can create higher switching costs, clinical integration advantages, and sustained adoption by hospitals and imaging centers over a multi-quarter horizon.
Top-line Growth Metric
Reported revenue growth of about 13.6% signals improving sales momentum. If sustained alongside the subscription model, this growth can compound recurring revenue, improve operational leverage and margins over several quarters, reducing dependency on external financing for operations.
Bears Say
Negative Margins And Operating Losses
Negative gross and net margins and persistent operating losses indicate the core business is not yet profitable. Over months this erodes reserves, limits reinvestment capacity, and makes breakeven harder to reach without sustained margin improvement or cost structure changes.
High Leverage And Weak Equity Base
A high debt-to-equity ratio and low equity ratio reduce financial flexibility and raise refinancing risk. Over the medium term this can increase interest burdens, constrain R&D and commercialization spending, and make the company more vulnerable to adverse funding conditions.
Negative Operating And Free Cash Flow
Negative operating and free cash flow point to ongoing cash burn and weak cash generation. Over several months this typically necessitates external financing or cost cuts, which can dilute shareholders or constrain growth investments and jeopardize long-term product rollouts.
Intrasense SA News
I8S FAQ
What was Intrasense SA’s price range in the past 12 months?
What is Intrasense SA’s market cap?
When is Intrasense SA’s upcoming earnings report date?
How were Intrasense SA’s earnings last quarter?
Is Intrasense SA overvalued?
Does Intrasense SA pay dividends?
What is Intrasense SA’s EPS estimate?
How many shares outstanding does Intrasense SA have?
What happened to Intrasense SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Intrasense SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Intrasense SA
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Stephen Armand
- Employees
- 76
- Website
- www.intrasense.fr
- Address
- 1231, avenue du Mondial 98, Montpellier, OCC, 34000, FR
Intrasense SA (I8S) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 14 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |








